CX 2026 Registration
CX Executive Board
CX 2026 Programme
CX 2026 – The 48th Charing Cross Symposium
The Charing Cross (CX) Symposium continues to set the standard in vascular and endovascular education, shaping the future of practice worldwide. CX 2026 marked the final chapter of our current three-year cycle, designed to spark debate on the biggest controversies in the field. Our distinguished faculty of global experts critically examined the evidence, exchanged perspectives, and worked towards building consensus on the issues that matter most.
Consensus was the defining theme for CX 2026. We welcomed an international community of specialists, educators, and innovators to tackle the pressing challenges in vascular and endovascular medicine—challenges that directly impact patient outcomes and clinical decision-making.
In 2024, CX found a new home at ExCeL London, unlocking fresh opportunities for immersive, hands-on learning. The expanded workshop programme has gone from strength to strength, offering delegates practical skills alongside groundbreaking evidence and innovation. In 2026, we returned once again to London’s premier conference and exhibition venue to deliver an agenda packed with cutting-edge science, expert debate, and future-shaping education.
Stay connected—sign up for the CX Newsletter and be the first to hear the latest updates.
CX Co-Chairs
Latest CX news
Live from CX 34: Slim majority do not believe drug elution is worthwhile
In an extremely close vote, 51% of delegates voted against the motion that drug elution is worthwhile for the management of occlusion of the infrainguinal arteries (vs. 49% who voted for the motion).
Supporting the motion were Thomas Zeller (Bad Krozingen, Germany) and Gunnar Tepe (Rosenheim, Germany) and against the motion were Stephan Duda (Berlin, Germany) and Iris Baugmartner (Bern, Switzerland).
Live from CX 34: TASC III – What is achievable?
William R Hiatt, Denver, USA, outlined what was achievable with TASC III at CX 34. He said TASC III was seeking to achieve a consensus between surgical and endovascular societies. “The response to TASC IIb was disappointing but current inter-societal engagement encouraging,” he noted.
On the question of whether it was possible to create a more integrated and clinically-relevant classification of peripheral arterial disease, he noted that TASC III would include the key components of: patient, limb and lesions.
He noted that TASC III would establish new standards for regulatory approval and reimbursement of new therapies. For critical limb ischaemia, it would expand on amputation-free survival to include healing of ischaemic ulcers, relief of ischaemic pain, avoidance of additional procedures and improvement in functional status, he said.
Live from CX 34: Endovascular techniques must be taught with interdisciplinary collaboration, 55% of CX delegates say
In a close vote, most delegates attending the first debate of CX 34 agreed with Sigrid Nikol, Hamburg, Germany, that endovascular techniques must be taught with interdisciplinary collaboration, with 55% supporting the motion vs. 45% who voted against the motion (and thus agreed with Frank Vermassen, Ghent, Belgium).
Nikol argued that the “excellent” results of endovascular therapy in clinical trials indicate that: “cardiologists, surgeons, radiologists, and other interventionists possessing peripheral vascular interventional skills can perform endovascular therapy safely despite different starting points.” On the other hand, Vermassen argued that training in endovascular techniques can and should be performed in vascular surgery training centres, saying: “Interdisciplinary collaboration is not a prerequisite for training in endovascular techniques.”